{"ATC Code":["N - Nervous system","N03 - Antiepileptics","N03A - Antiepileptics","N03AX - Other antiepileptics","N03AX09","N03AX09","N03AX09 - Lamotrigine","QN - Nervous system","QN03 - Antiepileptics","QN03A - Antiepileptics","QN03AX - Other antiepileptics","QN03AX09 - Lamotrigine"],"Abbreviation":["BW-430C","BW430C"],"Absorption, Distribution and Excretion":"Lamotrigine is rapidly and entirely absorbed with minimal first-pass metabolism effects, with a bioavailability estimated at 98%. Cmax is reached in the range of 1.4 to 4.8 hours post-dose, but this depends on the dose administered, concomitant medications, and epileptic status. The rate and extent of lamictal absorption is considered equivalent between the compressed tablet form taken with water to that of the chewable dispersible tablets, taken with or without water.","Adverse Effects":"United States Boxed Warning: Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of this medication. Rash severity varies but includes a risk for Stevens-Johnson syndrome. The incidence of Stevens-Johnson syndrome in the pediatric population is 0.3% to 0.8% and 0.03% to 0.08% in adult populations. The number of cases associated with toxic epidermal necrolysis is too low to report an estimated incidence. Nearly all cases of a rash occur 2 to 8 weeks after the initiation of lamotrigine. It should also bear mentioning that the discontinuation of lamotrigine may not prevent a rash from becoming life-threatening. Patient education should include continuous monitoring of the rash for improvement after discontinuing the medication.","Aliases":["6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine","Lamictal","Lamictal Cd","Lamotrigina","Lamictal XR","Lamotriginum","BW 430C","3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine","BW-430C","Lamictal ODT","1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-","3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine","BW430C","NSC-759171","SUBVENITE","GW 273293","CHEBI:6367","Dtxcid203195","Lamotirigine","Lamotrigine ER","LAMOTRIGINE Kit","lamotrigine extended-release","Lamotrigine Extended Release","lamotrigine chewable dispersible","N03AX09","281-901-8","658-035-8","Labileno","Lamitor","C9H7Cl2N5","Mfcd00865333","LTG;BW430C","CHEMBL741","Mls000069685","s3024","Ncgc00015605-06","Lamictin","Smr000058464","6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine","(6M)-6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine","Cas-84057-84-1","Sr-01000000187","Einecs 281-901-8","Lamictal;","Lamotrigine CRS","HSDB 7526","EUR-1048","IYJ","Opera_ID_12","Tocris-1611","Lamotrigine 100 microg/mL in Acetonitrile","Lopac-L-3791","L 3791","Lopac0_000688","Schembl35439","Mls000759486","Mls001077325","Mls001423991","Bidd:gt0794","Lamotrigine, \u003e=98%, powder","GTPL2622","orb1310392","orb3141187","Lamotrigine, 1mg/ml in Ethanol","Lamotrigine - Bio-X trade mark","Schembl29360953","Schembl29801510","HY-B0495R","GLXC-07355","HMS2051C10","HMS2089M08","HMS2093P21","HMS2230L04","HMS3262I17","HMS3268G17","HMS3371O16","HMS3393C10","HMS3657A17","HMS3715H21","HMS3885M03","HMS5081I06","Pharmakon1600-01505610","HY-B0495","Lamotrigine 1.0 mg/ml in Methanol","MSK10267","Tox21_110179","Tox21_500688","Bdbm50031299","EBC-03614","HB0368","NSC746307","NSC759171","STK628377","Akos005561147","Lamotrigine for system suitability CRS","Tox21_110179_1","6-(2,2,4-triazine-3,5-diyldiamine","CCG-100856","DB00555","ID58057","KS-1074","Lamotrigine for peak identification CRS","LP00688","NC00106","NSC 746307","NSC 759171","NSC-746307","Sdccgsbi-0050666.p003","Smp2_000303","Ncgc00015605-01","Ncgc00015605-02","Ncgc00015605-03","Ncgc00015605-04","Ncgc00015605-05","Ncgc00015605-07","Ncgc00015605-08","Ncgc00015605-09","Ncgc00015605-10","Ncgc00015605-23","Ncgc00015605-24","Ncgc00015605-25","Ncgc00022936-02","Ncgc00022936-04","Ncgc00022936-05","Ncgc00261373-01","AC-10298","AC-32483","BL166799","Sbi-0050666.p002","DB-014839","EU-0100688","L0241","NS00000354","SW197486-3","D00354","En300-120680","W13018","Ab00384359-16","Ab00384359_17","Ab00384359_18","F093440","3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine","Sr-01000000187-2","Sr-01000000187-4","Sr-01000000187-7","Brd-k93460210-001-22-9","Brd-k93460210-001-23-7","Brd-k93460210-071-01-6","Sr-01000000187-10","3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine","F2173-0540","Z1532338577","Lamotrigine Working Standard","Lamotrigine, British Pharmacopoeia (BP) Reference Standard","Lamotrigine, European Pharmacopoeia (EP) Reference Standard","1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)","6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine)","GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine","Lamotrigine, United States Pharmacopeia (USP) Reference Standard","Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material","Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard","Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard"],"Biological Half-Life":"The average elimination half-life of lamotrigine ranges from approximately 14-59 hours. The value is dependent on the dose administered, concomitant drug therapy, as well as disease status. One pharmacokinetic study revealed a half-life of 22.8 to 37.4 hours in healthy volunteers. It also reported that enzyme-inducing antiepileptic drugs such as pheobarbital, phenytoin, or carbamazepine decrease the half-life of lamotrigine. On the other hand, valproic acid increases the half-life of lamotrigine (in the range of 48-59 hours).","Boiling Point":"503.1±60.0","CAS":"84057-84-1","ChemicalClasses":["benzylamine"],"Chirality":"achiral","Color/Form":"White to pale cream-colored powder. Crystals from isopropanol","DBI-IGS":["Lamotrigine"],"DTXSID":"2023195","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Entries":0,"Lower":27.2,"Percentage":0,"Unit":"mg","Upper":25},"Extreme":{"Entries":0,"Lower":50,"Percentage":0,"Unit":"mg","Upper":50},"Heavy":{"Entries":0,"Lower":50,"Percentage":0,"Unit":"mg","Upper":50},"Light":{"Entries":10,"Lower":27.2,"Percentage":66.7,"Unit":"mg","Upper":27.2},"Strong":{"Entries":5,"Lower":25,"Percentage":33.3,"Unit":"mg","Upper":50}}}],"Drug Classes":["Breast Feeding","Lactation","Milk, Human","Anticonvulsants","Antimanic Agents","Antidepressive Agents"],"Drug Indication":"Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.  It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).  In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy.  Limitations of use  It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.","Drug Warnings":"/BOXED WARNING/ WARNING: SERIOUS SKIN RASHES. Lamictal can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving Lamictal. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking Lamictal as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.  Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by Lamictal. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of Lamictal with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of Lamictal, or (3) exceeding the recommended dose escalation for Lamictal. However, cases have occurred in the absence of these factors.  Nearly all cases of life-threatening rashes caused by Lamictal have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.  Although benign rashes are also caused by Lamictal, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, Lamictal should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring","Druglikeness":{"Lipinski":{"Passes":true,"Violations":0}},"DurationOfAction":"","EliminationHalfLife":"29 hours","Erowid Experience Reports":[],"Esters":[],"European Community (EC) Number":"281-901-8","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"U3H27498KS"}]}},{"Name":"Active Moiety","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"LAMOTRIGINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Anti-epileptic Agent"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"Physiologic Effects [PE] - Decreased Central Nervous System Disorganized Electrical Activity"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Mood Stabilizer"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"String":"Mechanisms of Action [MoA] - Organic Cation Transporter 2 Inhibitors"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":29,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Mechanisms of Action [MoA] - Dihydrofolate Reductase Inhibitors"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":41,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3878","Length":11,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Lamotrigine"},{"Extra":"CID-3878","Length":11,"Start":87,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/lamotrigine"},{"Extra":"CID-135398604","Length":13,"Start":151,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"},{"Extra":"CID-3878","Length":11,"Start":212,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/lamotrigine"}],"String":"Lamotrigine is an Anti-epileptic Agent and Mood Stabilizer. The mechanism of action of lamotrigine is as an Organic Cation Transporter 2 Inhibitor and Dihydrofolate Reductase Inhibitor. The physiologic effect of lamotrigine is by means of Decreased Central Nervous System Disorganized Electrical Activity."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":104,"Value":{"StringWithMarkup":[{"String":"LAMOTIRIGINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":104,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":23,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Mood Stabilizer [EPC]; Dihydrofolate Reductase Inhibitors [MoA]; Anti-epileptic Agent [EPC]; Organic Cation Transporter 2 Inhibitors [MoA]; Decreased Central Nervous System Disorganized Electrical Activity [PE]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":105,"Value":{"StringWithMarkup":[{"String":"LAMOTRIGINE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":105,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":170,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Decreased Central Nervous System Disorganized Electrical Activity [PE]; Organic Cation Transporter 2 Inhibitors [MoA]; Anti-epileptic Agent [EPC]; Mood Stabilizer [EPC]; Dihydrofolate Reductase Inhibitors [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":106,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3878","Length":11,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/LAMOTRIGINE"}],"String":"LAMOTRIGINE CHEWABLE DISPERSIBLE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":106,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Dihydrofolate Reductase Inhibitors [MoA]; Mood Stabilizer [EPC]; Anti-epileptic Agent [EPC]; Organic Cation Transporter 2 Inhibitors [MoA]; Decreased Central Nervous System Disorganized Electrical Activity [PE]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":107,"Value":{"StringWithMarkup":[{"String":"LAMOTRIGINE ER"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":107,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":170,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Decreased Central Nervous System Disorganized Electrical Activity [PE]; Organic Cation Transporter 2 Inhibitors [MoA]; Anti-epileptic Agent [EPC]; Mood Stabilizer [EPC]; Dihydrofolate Reductase Inhibitors [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":108,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3878","Length":11,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/LAMOTRIGINE"}],"String":"LAMOTRIGINE EXTENDED RELEASE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":108,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":28,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Anti-epileptic Agent [EPC]; Dihydrofolate Reductase Inhibitors [MoA]; Mood Stabilizer [EPC]; Decreased Central Nervous System Disorganized Electrical Activity [PE]; Organic Cation Transporter 2 Inhibitors [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":109,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3878","Length":11,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/LAMOTRIGINE"}],"String":"LAMOTRIGINE EXTENDED-RELEASE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":109,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-135398604","Length":13,"Start":28,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Dihydrofolate"}],"String":"Anti-epileptic Agent [EPC]; Dihydrofolate Reductase Inhibitors [MoA]; Mood Stabilizer [EPC]; Decreased Central Nervous System Disorganized Electrical Activity [PE]; Organic Cation Transporter 2 Inhibitors [MoA]"}]}}],"Formating":[],"HMDB ID":"HMDB0014695","Health Effects":"Serious skin rashes, acute multiorgan failure, blood dyscrasias, sudden unexplained death in epilepsy, withdrawal seizures. (A308) May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.","HeavyAtomCount":16,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anticonvulsants; Antimanic Agents; Antidepressive Agents","IUPACName":"6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine","InChI":"InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)","InChIKey":"PYZRQGJRPPTADH-UHFFFAOYSA-N","Interactions":"Rash, including serious and potentially life-threatening rash, appears to be more likely to occur in patients receiving concomitant valproic acid. Valproic acid can decrease clearance and increase plasma concentrations of lamotrigine more than twofold; exceeding the recommended reduced initial dosage of lamotrigine or the subsequent recommended schedule for escalation of lamotrigine dosage, particularly in patients receiving valproic acid, may increase the incidence of rash, including serious rash, in lamotrigine-treated patients. In clinical trials, 1% of adults and 1.2% of children receiving a drug regimen including immediate-release lamotrigine concomitantly with valproic acid experienced a rash requiring hospitalization, while 0.16% of adults and 0.6% of children receiving a drug regimen of lamotrigine without valproic acid were hospitalized because of rash.","MeSH Headers":[{"Id":"M0137818","Link":"https://id.nlm.nih.gov/mesh/M0137818.html","Name":"Lamotrigine","Ref":143},{"Id":"M0137815","Link":"https://id.nlm.nih.gov/mesh/M0137815.html","Name":"BW-430C","Ref":145},{"Id":"M0137816","Link":"https://id.nlm.nih.gov/mesh/M0137816.html","Name":"Lamictal","Ref":146},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":147},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":176},{"Id":"M0001382","Link":"https://id.nlm.nih.gov/mesh/M0001382.html","Name":"Anticonvulsants","Ref":177},{"Id":"M0003165","Link":"https://id.nlm.nih.gov/mesh/M0003165.html","Name":"Calcium Channel Blockers","Ref":178},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agents","Ref":179},{"Id":"M0379271","Link":"https://id.nlm.nih.gov/mesh/M0379271.html","Name":"Sodium Channel Blockers","Ref":180}],"MeSH Pharmacological Classification":[{"Id":"M0001382","Link":"https://id.nlm.nih.gov/mesh/M0001382.html","Name":"Anticonvulsant","Ref":177},{"Id":"M0003165","Link":"https://id.nlm.nih.gov/mesh/M0003165.html","Name":"Calcium Channel Blocker","Ref":178},{"Id":"M0021770","Link":"https://id.nlm.nih.gov/mesh/M0021770.html","Name":"Antipsychotic Agent","Ref":179},{"Id":"M0379271","Link":"https://id.nlm.nih.gov/mesh/M0379271.html","Name":"Sodium Channel Blocker","Ref":180}],"Mechanism of Action":"The exact mechanism of action of lamotrigine is not fully elucidated, as it may exert cellular activities that contribute to its efficacy in a range of conditions. Although chemically unrelated, lamotrigine actions resemble those of phenytoin and carbamazepine, inhibiting voltage-sensitive sodium channels, stabilizing neuronal membranes, thereby modulating the release of presynaptic excitatory neurotransmitters.   Lamotrigine likely acts by inhibiting sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate. The mechanism of action of lamotrigine in reducing anticonvulsant activity is likely the same in managing bipolar disorder. Studies on lamotrigine have identified its binding to sodium channels in a fashion similar to local anesthetics, which could explain the demonstrated clinical benefit of lamotrigine in some neuropathic pain states.   Lamotrigine displays binding properties to several different receptors. In laboratory binding assays, it demonstrates weak inhibitory effect on the serotonin 5-HT3 receptor. Lamotrigine also weakly binds to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor (KOR), mACh receptors and serotonin 5-HT2 receptors with an IC50\u003e100 µM. Weak inhibitory effects were observed at sigma opioid receptors. An in vivo study revealed evidence that lamotrigine inhibits Cav2.3 (R-type) calcium currents, which may also contribute to its anticonvulsant effects.","Melting Point":"177-181","Metabolism/Metabolites":"Lamotrigine is mainly glucuronidated, forming 2-N-glucuronide conjugate, a pharmacologically inactive metabolite. The total radioactivity detected after a 240mg radiolabeled dose of lamotrigine during clinical trials were as follows: lamotrigine as unchanged drug(10%), a 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), as well as various other minor metabolites (4%).","MolecularFormula":"C\u003csub\u003e9\u003c/sub\u003eH\u003csub\u003e7\u003c/sub\u003eCl\u003csub\u003e2\u003c/sub\u003eN\u003csub\u003e5\u003c/sub\u003e","MolecularWeight":"256.09 g/mol","Passes":true,"Pharmacodynamics":"Lamotrigine likely prevents seizures and prevents mood symptoms via stabilizing presynaptic neuronal membranes and preventing the release of excitatory neurotransmitters such as glutamate, which contribute to seizure activity.   A note on cardiovascular effects  The metabolite of lamotrigine, 2-N-methyl metabolite (formed by glucuronidation), is reported to cause dose-dependent prolongations of the PR interval, widening of the QRS complex, and at higher doses, complete AV block. Although this harmful metabolite is only found in trace amounts in humans, plasma concentrations may increase in conditions that cause decreased drug glucuronidation, such as liver disease.","Physical Description":"Solid","PubChemId":3878,"PubChemTitle":"Lamotrigine","RefChem":"5936","RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Lamotrigine","Name":"Lamotrigine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q410346","Name":"Lamotrigine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB00555","Name":"Lamotrigine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3878","Name":"Lamotrigine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=84057-84-1","Name":"Lamotrigine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014695","Name":"Lamotrigine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00354","Name":"Lamotrigine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/U3H27498KS","Name":"Lamotrigine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID2023195","Name":"Lamotrigine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3878, Lamotrigine. Accessed June 24, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3878\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3878\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 24, 2026. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N","SaltData":[],"Salts":[],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["2"],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"In water, 170 mg/L at 25 °C","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 107.632 57.536\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h108v58H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m32.325 56.43 13.198-7.62M32.325 53.614l10.759-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m45.523 48.81-.005-15.249\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m45.518 33.561-13.203-7.628M43.08 34.969l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m32.315 25.933-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m19.117 33.553.004 15.248M21.555 34.961l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m32.325 56.43-13.204-7.629M19.117 33.553 7.61 26.912M32.315 25.933l.002-11.047M45.518 33.561l13.198-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m58.716 25.941 13.2 7.618M61.155 24.534l10.76 6.209\"/\u003e\u003c/g\u003e\u003cpath d=\"m71.916 33.559 9.923-5.735\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m85.118 21.828.002-11.148M82.68 21.828l.001-9.74\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m85.118 21.828.001-5.574M82.68 21.828v-4.87\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m85.12 10.68-9.921-5.725\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m68.642 4.957-6.645 3.841M69.862 7.069l-6.645 3.84\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m68.642 4.957-3.322 1.92M61.997 8.798l3.323-1.921M69.862 7.069l-3.322 1.92M63.217 10.909l3.323-1.92\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m58.716 25.941.002-11.147M85.12 10.68l9.919-5.727M71.916 33.559l.003 11.14\" class=\"bond\"/\u003e\u003cpath fill=\"#1ff01f\" stroke=\"none\" d=\"M4.59 23.926v.714q-.339-.321-.726-.476-.387-.161-.822-.161-.857 0-1.315.524-.453.524-.453 1.518 0 .988.453 1.512.458.524 1.315.524.435 0 .822-.155.387-.16.726-.476v.703q-.357.244-.756.363-.393.119-.833.119-1.137 0-1.792-.691-.649-.696-.649-1.899 0-1.208.649-1.899.655-.696 1.792-.696.446 0 .839.119.399.119.75.357m1.02-.595h.614v5.209H5.61zM34.332 8.577v.714q-.339-.321-.726-.476-.387-.161-.821-.161-.858 0-1.316.524-.453.524-.453 1.518 0 .988.453 1.512.458.524 1.316.524.434 0 .821-.155.387-.161.726-.476v.702q-.357.244-.756.364-.393.119-.833.119-1.137 0-1.792-.691-.649-.696-.649-1.899 0-1.209.649-1.899.655-.697 1.792-.697.446 0 .839.119.399.12.75.358m1.021-.596h.613v5.209h-.613z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M83.224 23.428h.911l2.215 4.186v-4.186h.661v5.001H86.1l-2.221-4.185v4.185h-.655zM70.027.562h.911l2.215 4.185V.562h.661v5.001h-.911l-2.221-4.185v4.185h-.655zM56.825 8.193h.911l2.215 4.185V8.193h.661v5h-.911L57.48 9.008v4.185h-.655z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M96.425.56h.911l2.214 4.185V.56h.661v5.001H99.3l-2.22-4.185v4.185h-.655zM100.783.56h.678v2.048h2.459V.56h.673v5.001h-.673V3.179h-2.459v2.382h-.678zM105.654 6.745h1.418v.343h-1.908v-.343q.232-.24.629-.64.4-.403.503-.521.197-.218.272-.368.079-.154.079-.3 0-.239-.168-.389t-.436-.15q-.193 0-.404.067-.21.065-.453.197v-.407q.246-.1.457-.15.214-.05.389-.05.468 0 .743.232.279.232.279.625 0 .182-.072.35-.068.164-.25.389-.05.057-.321.336-.268.279-.757.779\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M70.027 46.299h.911l2.215 4.185v-4.185h.661V51.3h-.911l-2.221-4.185V51.3h-.655zM74.385 46.299h.679v2.048h2.458v-2.048h.673V51.3h-.673v-2.382h-2.458V51.3h-.679zM79.256 52.484h1.418v.343h-1.907v-.343q.232-.24.628-.64.4-.403.504-.521.196-.218.271-.368.079-.154.079-.3 0-.239-.168-.389t-.436-.15q-.193 0-.403.067-.211.065-.454.197v-.407q.246-.1.457-.15.214-.05.389-.05.468 0 .743.232.279.232.279.625 0 .182-.071.35-.068.164-.25.389-.05.057-.322.336-.268.279-.757.779\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#1ff01f\" d=\"m7.61 26.912 5.754 3.32M32.317 14.886l-.001 5.524\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m81.839 27.824-4.962 2.867M75.199 4.955l4.961 2.862M58.718 14.794l-.001 5.573M95.039 4.953l-4.96 2.863M95.039 4.953l-4.96 2.863M71.919 44.699l-.002-5.57M71.919 44.699l-.002-5.57\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Anticonvulsants; Calcium Channel Blockers; Excitatory Amino Acid Antagonists; Voltage-Gated Sodium Channel Blockers","Title":"Lamotrigine","Toxicity Data":"LD50: 250 (mg/kg) (mice) \nLD50: 250 (mg/kg) (rat)\nLD50\u003e 640 (mg/kg) (oral, rat) (Sawyer)\nLD50\u003e 640 (mg/kg) (oral, mice) (Sawyer)","Treatment":"There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced or gastric lavage should be performed; usual precautions should be taken to protect the airway. (A308)","UNII":"U3H27498KS","Violations":0,"Wikidata":"Q410346","Wikipedia":"Lamotrigine","XLogP":1.4}